A combination of three sets of evidence is recommended: (1) neuroimaging to detect early evidence of neurodegeneration in brain areas susceptible to AD pathology; (2) the genetic risk markers that predict AD onset; and (3) evidence of abnormalities in AD biomarkers (e.g., CSF Aβ42, tau, and p-tau) (Figure 2). The gene discussed is MAPT; the disease is Alzheimer disease.